Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
uMotif Buys ClinOne; Integrates Site Applications into eCOA/ePRO Platform for Clinical Trials
Crown Laboratories and Revance Announce Entry Into Merger Agreement
Calliditas Refinances Existing Term Loan with Euro 92 Million Senior Secured Facility with Athyrium Capital
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® for the Treatment of Cervical Dystonia
Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection